Short Interest in Kamada Ltd. (NASDAQ:KMDA) Increases By 33.3%

Kamada Ltd. (NASDAQ:KMDA) saw a significant growth in short interest in December. As of December 31st, there was short interest totalling 23,200 shares, a growth of 33.3% from the December 15th total of 17,400 shares. Based on an average trading volume of 63,600 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.1% of the company’s stock are sold short.

Kamada Stock Performance

Shares of KMDA stock opened at $7.16 on Friday. The stock has a market capitalization of $411.56 million, a price-to-earnings ratio of 25.57 and a beta of 0.98. Kamada has a one year low of $4.74 and a one year high of $8.00. The company’s 50-day simple moving average is $6.20 and its 200-day simple moving average is $5.76.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of Kamada in a research note on Friday, January 10th.

Institutional Investors Weigh In On Kamada

A hedge fund recently bought a new stake in Kamada stock. Public Employees Retirement System of Ohio bought a new stake in Kamada Ltd. (NASDAQ:KMDA) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 14,270 shares of the biotechnology company’s stock, valued at approximately $77,000. Hedge funds and other institutional investors own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.